TP53

Devdeep Mukherjee1, Rialnat A Lawal2, Courtney D Fitzhugh2

  • 1Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.

概括

在治疗前识别先前存在的TP53突变可以预测患上与治疗相关的髓状瘤的风险. 超深度DNA测序为这一关键风险评估提供了前性方法.